Nature Communications (Dec 2017)
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
- Dan A. Landau,
- Clare Sun,
- Daniel Rosebrock,
- Sarah E. M. Herman,
- Joshua Fein,
- Mariela Sivina,
- Chingiz Underbayev,
- Delong Liu,
- Julia Hoellenriegel,
- Sarangan Ravichandran,
- Mohammed Z. H. Farooqui,
- Wandi Zhang,
- Carrie Cibulskis,
- Asaf Zviran,
- Donna S. Neuberg,
- Dimitri Livitz,
- Ivana Bozic,
- Ignaty Leshchiner,
- Gad Getz,
- Jan A. Burger,
- Adrian Wiestner,
- Catherine J. Wu
Affiliations
- Dan A. Landau
- New York Genome Center
- Clare Sun
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health
- Daniel Rosebrock
- Broad Institute
- Sarah E. M. Herman
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health
- Joshua Fein
- New York Genome Center
- Mariela Sivina
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Chingiz Underbayev
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health
- Delong Liu
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health
- Julia Hoellenriegel
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Sarangan Ravichandran
- Advanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc
- Mohammed Z. H. Farooqui
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health
- Wandi Zhang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Carrie Cibulskis
- Broad Institute
- Asaf Zviran
- New York Genome Center
- Donna S. Neuberg
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute
- Dimitri Livitz
- Broad Institute
- Ivana Bozic
- Department of Applied Mathematics, University of Washington
- Ignaty Leshchiner
- Broad Institute
- Gad Getz
- Broad Institute
- Jan A. Burger
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Adrian Wiestner
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health
- Catherine J. Wu
- Broad Institute
- DOI
- https://doi.org/10.1038/s41467-017-02329-y
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 12
Abstract
In a subset of patients with chronic lymphocytic leukemia (CLL) treated with targeted agents, such as ibrutinib, drug resistant subclones emerge. Here, the authors report on transcriptional changes in CLL patients treated with ibrutinib and identify early clonal shifts associated with evolution of resistant clones.
